Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Post-term deliveries associated with increased short-term risks to newborns

Post-term deliveries associated with increased short-term risks to newborns

While pregnancy is considered full-term at 40 weeks, only some 5 percent of women actually give birth on their predetermined due date. Most OBGYNs recommend more frequent and more vigilant monitoring after 40 weeks and sometimes the artificial induction of labor. But many pregnant women refuse induction due to the risk of stress to the fetus or increased likelihood of requiring a caesarean section. [More]
UCA researchers create new animal models to study link between diabetes and Alzheimer's disease

UCA researchers create new animal models to study link between diabetes and Alzheimer's disease

In recent time, many epidemiological studies have proved very close links existing between diabetes and Alzheimer´s disease. In fact, it has been stated that diabetes is a significant risk factor for suffering from Alzheimer and vascular dementia, the two main causes of dementia. [More]
ß-Hydroxybutyrate LiquiColor® reagent system to detect ketosis

ß-Hydroxybutyrate LiquiColor® reagent system to detect ketosis

Stanbio Laboratory, an EKF Diagnostics company, has developed the ß-Hydroxybutyrate LiquiColor® Reagent System to improve the detection of clinically significant ketosis. [More]
Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad. [More]
UAB study to examine social support, intuitive eating impact on older African-American men with diabetes

UAB study to examine social support, intuitive eating impact on older African-American men with diabetes

University of Alabama at Birmingham School of Nursing Assistant Professor Loretta T. Lee, Ph.D., has received a 2015 Deep South Resource Center for Minority Aging pilot grant award to examine the association of social support and intuitive eating with glycemic control in older African-American men with diagnosed type 2 diabetes. [More]
Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor. [More]
Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Patients suffering from diabetic foot have significantly impaired cognitive function

Patients suffering from diabetic foot have significantly impaired cognitive function

In a first-time study, Ben-Gurion University of the Negev researchers revealed a new finding in people with diabetes who suffer from "diabetic foot." Patients with this condition also have significantly impaired cognitive function. [More]
Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs. [More]
IQWiG: Benefit of proteome analysis for detection of diabetic nephropathy remains unclear

IQWiG: Benefit of proteome analysis for detection of diabetic nephropathy remains unclear

The German Institute for Quality and Efficiency in Health Care examined the benefit of a diagnostic-therapeutic strategy using urinary proteome analysis for detection of diabetic nephropathy (DN) versus a conventional diagnostic strategy in patients with diabetes mellitus and arterial hypertension. After publication of the preliminary report in June 2015, interested persons and parties had the opportunity to comment on the preliminary results. [More]
T1DM therapeutics market expected to reach $7.1 billion by 2021

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%. [More]
Breastfeeding may offer unique benefits to women, protect against type 2 diabetes after delivery

Breastfeeding may offer unique benefits to women, protect against type 2 diabetes after delivery

Women with gestational diabetes who consistently and continuously breastfeed from the time of giving birth are half as likely to develop type 2 diabetes within two years after delivery, according to a study from Kaiser Permanente published today in Annals of Internal Medicine. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT). [More]
Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

Scientists succeed in promoting regeneration of injured neurons in zebrafish by the use of light

The nervous system is built to last a lifetime, but diverse diseases or environmental insults can overpower the capacity of neurons to maintain function or to repair after trauma. A team led by Dr. Hernán López-Schier, head of the Research Unit Sensory Biology and Organogenesis at Helmholtz Zentrum München, now succeeded in promoting the repair of an injured neural circuit in zebrafish. [More]
Gestational diabetes mellitus screening provides more health benefits to pregnant women

Gestational diabetes mellitus screening provides more health benefits to pregnant women

A local research study conducted by KK Women's and Children's Hospital and Duke-NUS Graduate Medical School has found that pregnant patients benefit most from gestational diabetes mellitus (GDM) screening as it allows for timely interventions and brings about health benefits that far outweigh the cost. [More]
Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA. [More]
Diabetes prevention begins in the womb

Diabetes prevention begins in the womb

60 million people worldwide are living with diabetes mellitus, and one in ten people over the age of 25 will develop the condition (type 2) at some stage in their lives. Globally, around 3.4 million people die from diabetes and its consequences every year. "Every six seconds, somebody somewhere in the world dies from diabetes", says Alexandra Kautzky-Willer from the Department of Endocrinology and Metabolism at the MedUni Vienna's University Department of Internal Medicine III. [More]
New funding for Centenary's life saving research

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today. [More]
Advertisement